C-Reactive Protein (Latex) High Sensitive Test System for Cobas Integra Instruments
Cardiac C-Reactive Protein, Antigen, Antiserum, And Control. 510(k) K053603, from Roche Diagnostics Corp. (Indianapolis, IN). Product code NQD, class 2.
As of Nov 20, 2026, K053603 is an FDA 510(k) held by Roche Diagnostics Corp., substantially equivalent on Feb 9, 2006 after 48 days, with no recalls tied to it in FDA's recall database.
- Review time: 48 days
- Recalls: 0
- Cited as a predicate by: 2 devices
The CRP (Latex) High Sensitive Immunoturbidimetric assay is for the in vitro quantitative determination of C-reactive protein (CRP) in human serum and plasma on Roche automated clinical chemistry analyzers. Measurement of CRP is of use for the detection and evaluation of inflammatory disorders and associated diseases, infection and tissue injury.
- Tina-Quant Crp (Latex) HS Test System (C-Reactive Protein (Latex) High Sensitive)K042485 · Roche Diagnostics Corp. · Oct 29, 2004
- N High Sensitivity CrpK033908 · Dade Behring, Inc. · Jan 22, 2004
- Tina-quant Cardiac high sensitivity CRP IIIK260026 · Roche Diagnostics · Apr 2, 2026
- Optilite High Sensitivity C-Reactive Protein KitK180099 · The Binding Site Group , Ltd. · Oct 12, 2018
- Tina-quant Cardiac high sensitivity CRP IIIK260026 · Roche Diagnostics · Apr 2, 2026
- Atellica® CH High Sensitivity C-Reactive Protein 2 (hCRP2)K233242 · Siemens Healthcare Diagnostics, Inc. · Jan 18, 2024
- CardioPhase® hsCRPK212559 · Siemens Healthcare Diagnostics Products GmbH · Dec 16, 2022
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Dec 23, 2005
- Review panel
- Immunology
- Regulation
- 21 CFR 866.5270
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files